The weekly litigation news digest is live. Subscribe now

Trans-4-{2-[4-(2,3-Dichlorophenyl)-Piperazin-1-Yl]-Ethyl}-N,N-Dimethylcarbamoyl-Cyclohexylamine For Treating Negative Symptoms Of Schizophrenia

Patent No. EP2925324 (titled "Trans-4-{2-[4-(2,3-Dichlorophenyl)-Piperazin-1-Yl]-Ethyl}-N,N-Dimethylcarbamoyl-Cyclohexylamine For Treating Negative Symptoms Of Schizophrenia") was filed by Richter Gedeon Nyrt on Nov 28, 2013. The application was issued on Dec 30, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
KRKASep 30, 2021HOEFER & PARTNER PATENTANWALTE MBB
WITTKOPPSep 29, 2021HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2925324

RICHTER GEDEON NYRT
Application Number
EP13805597A
Filing Date
Nov 28, 2013
Status
Opposition Rejected
May 16, 2025
Publication Date
Dec 30, 2020
External Links
Slate, Register, Google Patents